December 10, 2005

Zometa Prevents Osteoporosis in Prostate Cancer Patients

A multicenter trial has confirmed that Zometa (zoledronic acid) given for one year prevents bone loss in patients with metastatic prostate cancer who are undergoing hormone therapy. The details of this phase II study were reported in the November 2005 issue of Urology. (CancerConsultants.com)


comments.gif

My husband has prostate cancer. His urologist sent him for a bone density scan, it came back low. Dr. now says to have the zometa injections. What are the pros and cons of this drug?


Talk about this story




Remember Me?



Related Stories

More News Topics:
Breast Cancer      Alternative Medicine      Infectious Disease       Eating Disorders       Sleep      Orthopedic      Allergies      Neurological Disorders      Chronic Pain       Senior Health       Heart Health      Mental Health       Autoimmune Disorders       Women's Health
All content published on HealthDiaries.com is provided for informational and educational purposes only. HealthDiaries.com does not provide medical advice, diagnosis or treatment. The site and its services are not a substitute for professional medical advice and treatment. Always seek the advice of your doctor before making any changes to your health routine or treatment.

Copyright © 2004-2005 HealthDiaries.com. All rights reserved.